Top

Supportive Care in Cancer

Published in:

01-05-2009 | Short Communication

The role of methadone in opioid rotation—a Polish experience

Author: Wojciech Leppert

Published in: Supportive Care in Cancer | Issue 5/2009

Abstract

Background

To assess methadone analgesia, adverse effects, and calculation method of equianalgesic doses with oral morphine.

Materials and methods

Methadone was administered to 21 opioid-tolerant cancer patients because of pain (numerical rating scale [NRS] > 5) on morphine (ten patients), transdermal fentanyl (TF; four patients), morphine, ketamine, and TF (one patient), tramadol (one patient), pethidine (one patient), pain with drowsiness on morphine with ketamine (three patients), and pain with nausea on morphine (one patient). Dose ratios of equivalent daily dose of oral morphine (ddom) to daily dose of oral methadone (ddomet) were 4:1 (ddom to 100 mg), 6:1 (101–300 mg), 12:1 (301–1,000 mg), and 20:1 (over 1,000 mg). Previous opioid treatment was stopped completely (stop–start approach) in 19 patients; two received methadone and other opioids. The mean ddom before switch was 812 ± 486 mg. Methadone was administered regularly three times daily; 20 patients received oral methadone, one patient received rectal suppositories. Breakthrough pain was treated with methadone (half of regular dose), morphine, fentanyl, metamizol, ketoprofen, or ketamine.

Results

Mean time of methadone treatment was 38.3 ± 27.1 days (range 3–95 days), mean daily doses: start 48.1 ± 19.7 mg, maximal 148.5 ± 104.1 mg, treatment completion 131.1 ± 104.3 mg. Good analgesia (NRS < 4) was observed in 11 patients, partial (NRS 4–5) in nine patients, and unsatisfactory (NRS > 5) in one patient. Adverse effects such as drowsiness (six patients), constipation (six patients), nausea and vomiting (two patients), sweating (two patients), and respiratory depression (one patient) the last one resolved by methadone cessation and naloxone.

Conclusions

Results confirmed high analgesic efficacy, acceptable methadone adverse event profile, safety, and effectiveness of ddom to ddomet dose calculation method.

Ayonrinde OT, Bridge DT (2000) The rediscovery of methadone for cancer pain management. Med J Aust 173:536–540PubMed

Bolan EA, Tallarida RJ, Pasternak GW (2002) Synergy between μ opioid ligands: evidence for functional interactions among μ opioid receptor subtypes. J Pharmacol Exp Ther 303:557–562 doi:10.1124/jpet.102.035881 PubMedCrossRef

Bruera E, Palmer JN, Bosnjak S, Rico MA, Moyano J et al (2004) Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 22(1):185–192 doi:10.1200/JCO.2004.03.172 PubMedCrossRef

Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J (1996) Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857 doi:10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-TPubMedCrossRef

Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V, Expert Working Group of the European Association of Palliative Care Network (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19(9):2542–2554PubMed

Codd EE, Schank RP, Schupsky JJ, Raffa RB (1995) Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 274:1263–1270PubMed

Daeninck PJ, Bruera E (1999) Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of four cases. J Pain Symptom Manage 18(4):303–309 doi:10.1016/S0885-3924(99)00086-X PubMedCrossRef

Davies MP (2005) Look before leaping: combined opioids may not be the rave. Support Care Cancer 13(10):769–774 doi:10.1007/s00520-005-0839-y CrossRef

Davis MP, Walsh D (2001) Methadone for relief of cancer pain: a review of pharmacokinetics, pharmacodynamics, drug interactions and protocols of administration. Support Care Cancer 9:73–83 doi:10.1007/s005200000180 PubMedCrossRef

10.

De Conno F, Groff L, Brunelli C, Zecca E, Ventafridda V, Ripamonti C (1996) Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 14(10):2836–2842PubMed

11.

De Stoutz ND, Bruera E, Suazer-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10(5):378–384 doi:10.1016/0885-3924(95)90924-C PubMedCrossRef

12.

Ebert B, Andersen S, Krogsgaard-Larsen P (1995) Ketobemidone, methadone and pethidine are non-competitive N-methyl-d-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 187:165–168 doi:10.1016/0304-3940(95)11364-3 PubMedCrossRef

13.

Enting RH, Oldenmenger WH, van der Rijt CCD, Wilms EB, Elfrink EJ, Elswijk I, Sillevis Smitt PAE (2002) A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer 94:3049–3056 doi:10.1002/cncr.10518 PubMedCrossRef

14.

Fishman SM, Wilsey B, Mahajan G, Molina P (2002) Methadone reincarnated: novel clinical applications with related concerns. Pain Med 3(4):339–348 doi:10.1046/j.1526-4637.2002.02047.x PubMedCrossRef

15.

Gannon G (1997) The use of methadone in the care of dying. Eur J Palliat Care 4(5):152–158

16.

Gazelle G, Fine PG (2004) Methadone for pain. J Palliat Med 7(2):303–304 doi:10.1089/109662104773709431 PubMedCrossRef

17.

Hagen NA, Wasylenko E (1999) Methadone: outpatient titration and monitoring strategies in cancer patients. J Pain Symptom Manage 18(5):369–375 doi:10.1016/S0885-3924(99)00083-4 PubMedCrossRef

18.

Hanks GW, de Conno F, Cherny N, Hanna M, Kalso E, McQuay HJ, Mercadante S, Meynadier J, Poulain P, Ripamonti C, Radbruch L, Roca i Casas J, Säwe J, Twycross RG, Ventafridda V, Expert Working Group of the Research Network of the European Association for Palliative Care (2001) Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 84(5):587–593PubMedCrossRef

19.

Kotlińska-Lemieszek A, Łuczak J (2004) Subanesthetic ketamine: an essential adjuvant for intractable cancer pain. J Pain Symptom Manage 28(2):100–102 doi:10.1016/j.jpainsymman.2004.04.005 PubMedCrossRef

20.

Lawlor PG, Turner KS, Hanson J, Bruera ED (1998) Dose ratio between morphine and methadone in patients with cancer pain. A retrospective study. Cancer 82(6):1167–1183 doi:10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3 PubMedCrossRef

21.

Leppert W, Luczak J (2005) The role of methadone in cancer pain treatment—Polish experience. Prog Palliat Care 13(5):269–276 doi:10.1179/096992605X75868 CrossRef

22.

Lussier D, Huskey AG, Portenoy RK (2004) Adjuvant analgesics in cancer pain management. Oncologist 9:571–591 doi:10.1634/theoncologist.9-5-571 PubMedCrossRef

23.

Mancini IL, Hanson J, Neumann CM, Bruera E (2000) Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med 3(1):49–56 doi:10.1089/jpm.2000.3.49 PubMedCrossRef

24.

Manfredi PL, Foley KM, Payne R, Houde R, Inturissi CE (2003) Parenteral methadone: an essential medication for the treatment of pain. J Pain Symptom Manage 26(2):687–688 doi:10.1016/S0885-3924(03)00259-8 PubMedCrossRef

25.

Mercadante S (1999) Opioid rotation for cancer pain. Rationale and clinical aspects. Cancer 86:1856–1866 doi:10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G PubMedCrossRef

26.

Mercadante S (1998) Predictive factors and opioid responsiveness in cancer pain. Eur J Cancer 34(5):627–631 doi:10.1016/S0959-8049(97)10053-3 PubMedCrossRef

27.

Mercadante S (2004) Switching to methadone: “ad libitum” or fixed dose ratio? Palliat Med 18:71 doi:10.1191/0269216304pm945rr PubMedCrossRef

28.

Mercadante S, Bianchi M, Villari P, Ferrera P, Casuccio A, Fulfaro F, Gebbia V (2003) Opioid plasma concentration during switching from morphine to methadone: preliminary data. Support Care Cancer 11(5):326–331PubMed

29.

Mercadante S, Casuccio A, Agnello A, Barresi L (1999) Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage 18(3):188–192 doi:10.1016/S0885-3924(99)00048-2 PubMedCrossRef

30.

Mercadante S, Casuccio A, Calderone L (1999) Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 17(10):3307–3312PubMed

31.

Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, Gebbia V, Ripamonti C (2001) Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19(11):2898–2904PubMed

32.

Mercadante S, Ferrera P, Villari P, Arcuri E (2003) Hyperalgesia: an emerging iatrogenic syndrome. J Pain Symptom Manage 26(2):769–775 doi:10.1016/S0885-3924(03)00258-6 PubMedCrossRef

33.

Mercadante S, Villari P, Ferrera P, Casuccio A (2004) Addition of a second opioid may improve opioid response in cancer pain: preliminary data. Support Care Cancer 12(11):762–766 doi:10.1007/s00520-004-0650-1 PubMedCrossRef

34.

Morley J, Mankin M (1998) The use of methadone in cancer pain poorly responsive to other opioids. Pain Rev 5:51–58 doi:10.1191/096813098673619329 CrossRef

35.

Moryl N, Santiago-Palma J, Kornick C, Derby S, Fischberg D, Payne R, Manfredi PL (2002) Pitfalls of opioid rotation: substituting another opioid for methadone in patients with cancer pain. Pain 96:325–328 doi:10.1016/S0304-3959(01)00465-1 PubMedCrossRef

36.

Ripamonti C, Bianchi M (2002) The use of methadone for cancer pain. Hematol Oncol Clin North Am 16(3):543–555 doi:10.1016/S0889-8588(02)00017-5 PubMedCrossRef

37.

Ripamonti C, Bianchi M, Bruera E (2004) Methadone: an orphan drug? J Palliat Med 7(1):73–74 doi:10.1089/109662104322737278 PubMedCrossRef

38.

Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16(10):3216–3221PubMed

39.

Ripamonti C, Zecca E, Brunelli C, Rizzio E, Salta L, Lodi F, De Conno F (1995) Rectal methadone in cancer patients with pain. A preliminary clinical and pharmacokinetic study. Ann Oncol 6:841–843PubMed

40.

Simmonds MA, Payne R, Richenbacher J, Moran K, Southam NA, Hershey MS (1989) TTS (fentanyl) in the management of pain in patients with cancer. Proc Am Soc Clin Oncol 8:324

41.

Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100(1):4–22 doi:10.1111/j.1742-7843.2007.00017.x PubMedCrossRef

42.

Twycross R, Back I (1998) Nausea and vomiting in advanced cancer. Eur J Palliat Care 5(2):39–45

43.

Watanabe S, Belzile M, Kuehn N, Hanson J, Bruera E (1996) Capsules and suppositories of methadone for patients on high-dose opioids for cancer pain: clinical and economic considerations. Cancer Treat Rev 22(suppl. 1):131–136 doi:10.1016/S0305-7372(96)90075-4 PubMedCrossRef

44.

Weschules DJ, Bain KT (2008) A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 9(5):595–612 doi:10.1111/j.1526-4637.2008.00461.x PubMedCrossRef

45.

Weschules DJ, Bain KT, Richeimer S (2008) Actual and potential drug interactions associated with methadone. Pain Med 9(3):315–344 doi:10.1111/j.1526-4637.2006.00289.x PubMedCrossRef

Title: The role of methadone in opioid rotation—a Polish experience
Author: Wojciech Leppert
Publication date: 01-05-2009
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 5/2009
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-008-0537-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2009

Nurse-led rehabilitation after gynaecological cancer surgery

The Medical Care Continuity (MCC) project. A pilot study of video-assisted home care within the eTEN European Community program. The Italian experience

Catastrophic bleeds during end-of-life care in haematology: controversies from Australian research

Hospitalizations for infection in cancer patients: impact of an aging population

A questionnaire study of the approach to the anorexia–cachexia syndrome in patients with cancer by staff in a district general hospital

Nurses’ knowledge, attitudes, and practices regarding provision of sexual health care in patients with cancer: critical review of the evidence

Keynote webinar | Spotlight on antibody–drug conjugates in cancer